NMPA Greenlights IND Submission for Initial Clinical Trial Using HLX53 Anti-TIGIT Fc Fusion Protein in Conjunction with HANSIZHUANG and HANBEITAI for Early Treatment in Patients with Advanced or Metastatic Liver Cancer.

April 23rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Vertex Pharmaceuticals reports advancements in its suzetrigine pain treatment program. Suzetrigine, also known as VX-548, is an oral NaV1.8 inhibitor that could be the first new painkiller class for acute and neuropathic pain in two decades.

In the field of tumor treatment, antibody-drug conjugates (ADCs) have the potential to enhance the efficacy and specificity of cancer therapy by combining monoclonal antibodies with potent cytotoxic drugs.

4.15-4.21 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

Interchangeability in biosimilars means they match the original biological drug in quality, safety, and effectiveness, producing identical clinical outcomes.

April 20th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Pathios Therapeutics Secures $25M in Series B Funding for Cancer Drug Development.

Telomir Pharmaceuticals Reveals Promising Early Results for Anti-Aging Medication Telomir-1 at a Press Event in Washington, D.C.

Principles of Sustained and Controlled Drug Release for Extended Efficacy and Stable Blood Levels.

Subcutaneous Ocrevus, by Genentech, Shows Almost Total Control of Clinical Relapses and Brain Lesions Over a Year in Progressive and Relapsing MS Cases.

In March, British pharmaceutical giant AstraZeneca announced its intention to acquire Amolyt Pharma, a clinical-stage biotechnology company focused on developing innovative therapies for rare endocrine diseases.